Simple ratio analysis of18F-fluorodopa uptake in striatal subregions separates patients with early parkinson disease from healthy controls

Journal of Nuclear Medicine

Volumn 50, Issue 6, 2009, Pages 893-899

  Jokinen, Pekka ^a,c   Helenius, Hans ^b   Rauhala, Elina ^a   Brück, Anna ^a   Eskola, Olli ^a   Rinne, Juha O ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c TURKU PET CENTRE   (Finland)

Author keywords

18F FDOPA; Parkinson disease; PET; Quantification

Indexed keywords

6 FLUORODOPA F 18;

ADULT; ARTICLE; BRAIN REGION; CAUDATE NUCLEUS; CONTROLLED STUDY; CORPUS STRIATUM; DIFFERENTIAL DIAGNOSIS; DOPAMINERGIC SYSTEM; EARLY DIAGNOSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OCCIPITAL CORTEX; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; QUANTITATIVE ANALYSIS; RELIABILITY; SYMPTOMATOLOGY;

AGED; CORPUS STRIATUM; DIAGNOSIS, DIFFERENTIAL; DIHYDROXYPHENYLALANINE; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; ROC CURVE;

EID: 66649111082     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.061572     Document Type: Article

References (40)

1. Garnett ES, Nahmias C, Firnau G. Central dopaminergic pathways in hemiparkinsonism examined by positron emission tomography. Can J Neurol Sci. 1984;11:174-179. (Pubitemid 14133463)
2. Leenders KL, Palmer AJ, Quinn N, et al. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry. 1986;49:853-860. (Pubitemid 16048411)
3. Nahmias C, Garnett ES, Firnau G, Lang A. Striatal dopamine distribution in parkinsonian patients during life. J Neurol Sci. 1985;69:223-230. (Pubitemid 15074618)
4. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease: pathophysiologic and clinical implications. N Engl J Med. 1988;318:876-880. (Pubitemid 18090271)
5. 18F]dopa metabolism in the striatum in Parkinson's disease. Brain. 1996;119:2097-2103.
6. 18F]fluoro-L-dopa PET study. Mov Disord. 2001;16:608-615.
7. 18F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease. Synapse. 2001;40:193-200.
8. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain. 1999;122:1437-1448.
9. Takikawa S, Dhawan V, Chaly T, et al. Input functions for 6-[fluorine- 18]fluorodopa quantitation in parkinsonism: comparative studies and clinical correlations. J Nucl Med. 1994;35:955-963. (Pubitemid 24168123)
10. Vingerhoets FJ, Schulzer M, Ruth TJ, Holden JE, Snow BJ. Reproducibility and discriminating ability of fluorine-18-6-fluoro-L-dopa PET in Parkinson's disease. J Nucl Med. 1996;37:421-426. (Pubitemid 26094264)
11. Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry. 1998;64:314-319. (Pubitemid 28159833)
12. 18F]fluoro-L-dopa metabolism in living human brain: a comparison of six analytical methods. J Cereb Blood Flow Metab. 1993;13:57-69.
13. DeJesus OT, Endres CJ, Shelton SE, Nickles RJ, Holden JE. Evaluation of fluorinated m-tyrosine analogs as PET imaging agents of dopamine nerve terminals: comparison with 6-fluoroDOPA. J Nucl Med. 1997;38:630-636. (Pubitemid 27163662)
14. Ishikawa T, Dhawan V, Chaly T, et al. Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease. J Nucl Med. 1996;37:216-222. (Pubitemid 26150891)
15. Ishikawa T, Dhawan V, Kazumata K, et al. Comparative nigrostriatal dopaminergic imaging with iodine-123-bCIT-FP/SPECT and fluorine-18-FDOPA/PET. J Nucl Med. 1996;37:1760-1765. (Pubitemid 26378356)
16. Nakamura T, Dhawan V, Chaly T, et al. Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease. Ann Neurol. 2001;50:181-187. (Pubitemid 32738142)
17. Dhawan V, Ma Y, Pillai V, et al. Comparative analysis of striatal FDOPA uptake in Parkinson's disease: ratio method versus graphical approach. J Nucl Med. 2002;43:1324-1330.
18. 18F]dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiatry. 1995;59:597-600.
19. Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol. 1993;50:140-148. (Pubitemid 23054795)
20. 2. Radiochim Acta. 2008;96:845-848.
21. Pelizzari CA, Chen GT, Spelbring DR, Weichselbaum RR, Chen CT. Accurate three-dimensional registration of CT, PET, and/or MR images of the brain. J Comput Assist Tomogr. 1989;13:20-26. (Pubitemid 19042086)
22. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data: generalizations. J Cereb Blood Flow Metab. 1985;5:584-590. (Pubitemid 16218234)
23. Agresti A. Categorical Data Analysis. 2nd ed. New York, NY: Wiley- Interscience; 2002:710.
24. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837-845. (Pubitemid 18243017)
25. DeBari VA. Computation of decision levels from differentiated logistic regression probability curves. Ann Clin Lab Sci. 2006;36:194-200.
26. 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol. 1990;28:547-555.
27. 18F]fluoro-L-dopa uptake in early Parkinson's disease: a two-year follow-up study. Mov Disord. 2006;21:958-963.
28. 18F-dopa uptake: absence of an aging effect. J Cereb Blood Flow Metab. 1993;13:881-888.
29. Sawle GV, Colebatch JG, Shah A, Brooks DJ, Marsden CD, Frackowiak RS. Striatal function in normal aging: implications for Parkinson's disease. Ann Neurol. 1990;28:799-804.
30. Eshuis SA, Jager PL, Maguire RP, Jonkman S, Dierckx RA, Leenders KL. Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson's disease and healthy controls. Eur J Nucl Med Mol Imaging. 2009; 36:454-462.
31. Marek K, Jennings D, Seibyl J, et al. Long-term follow-up of patients with scans without evidence of dopaminergic deficit (SWEDD) in the ELLDOPA study [abstract]. Neurology. 2005;64(suppl 1):A274.
32. Eckert T, Feigin A, Lewis DE, Dhawan V, Frucht S, Eidelberg D. Regional metabolic changes in parkinsonian patients with normal dopaminergic imaging. Mov Disord. 2007;22:167-173. (Pubitemid 46374756)
33. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol. 2003;54:93-101. (Pubitemid 36764985)
34. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004;351:2498-2508. (Pubitemid 39603163)
35. 123I]beta-CIT SPECT in clinical practice? J Neurol Neurosurg Psychiatry. 2005;76:1211-1216.
36. Brooks DJ, Salmon EP, Mathias CJ, et al. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. Brain. 1990;113:1539-1552. (Pubitemid 20385930)
37. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181-184.
38. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology. 2001;57:1497-1499. (Pubitemid 32995738)
39. Schapira AH, Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann Neurol. 2006;59:559-562.
40. Aminoff MJ. Treatment should not be initiated too soon in Parkinson's disease. Ann Neurol. 2006;59:562-564. (Pubitemid 43358079)